Abstract:IntroductionImmunotherapy is changing the standard of care in cancer treatment. Immune checkpoint blockers (ICBs) that block the checkpoint programs used by tumor cells to inhibit the immune response have been approved by the US Food and Drug Administration with varying efficacy across cancer types. Given the clear benefits of ICB in some patients, there is an urgent research need to understand the determinants of ICB efficacy so more patients can benefit. To this end, there is growing interest in the interactions between immune cells and tumor cells as well as other extrinsic factors that can impact ICB therapy. Recent studies have shown that the microbiome can modulate the efficacy of immunotherapy. Specifically, clinical and therapeutic outcomes improved in a subset of ICB-refractory patients treated with fecal microbiota transplants (FMTs) from melanoma patients who responded to ICB therapy in combination with additional cycles of ICB therapy suggesting a synergistic effect of the gut microbiome. However, there is limited information and often inconsistencies among studies about the effect of bacteria on the immune system and checkpoint immunotherapy.MethodologyTo study the mechanisms by which the gut microbiome affects components of the immune system and response to ICB, we developed a mechanistic mathematical model for tumor growth in terms of immune components as features. The model simulates the temporal changes in the immune system during tumor progression and checkpoint immunotherapy. More specifically, the model simulates the tumor cells, relevant immune cells, and cytokines. The model was used for the reproduction of tumor growth curves from several preclinical FMT studies with ICB treatment. To determine the possible effect of the microbiome on the immune components, existing statistical approaches were used between experimental microbiome data and the immune components of the model.ResultsThe mathematical model was able to reproduce the experimental tumor growth curves by varying only two critical parameters. These parameters identify two possible mechanisms by which the gut microbiome can influence the immune response: i) the killing potential of tumor cells by immune cells and ii) the activation of the adaptive immune system. Furthermore, the model predictions agree with the observation that ICB treatment is only effective with FMT from responder patients. Additionally, the association analysis was able to identify specific microbes that induce positive and negative effects for ICB, and how these microbes affect various components of the immune system.ConclusionOur analysis identifies possible mechanisms by which the microbiome affects checkpoint immunotherapy and predicts not only which constituents of the microbiome have positive and negative effects but also identifies how these microbes are related to immune mechanisms. This information could be valuable for designing future targeted studies to validate these possible mechanisms at the cell and molecular levels. Citation Format: Constantinos Harkos, Andreas Hadjigeorgiou, Aditya K. Mishra, Golnaz Morad, Sarah Johnson, Nadim J. Ajami, Triantafyllos Stylianopoulos, Lance L. Munn, Jeniffer A. Wargo, Rakesh K. Jain. Modulation of cancer immunotherapy by the microbiome: Insights from computational analyses of preclinical studies [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl) nr B39.

Abstract 6686: The mechanism of gut microbiome-mediated immune activation on the clinical efficacy of PD-1 blocking treatment in solid tumors

Abstract 4298: the Gut Microbiome is Associated with Clinical Responses to Anti-Pd-1 Immunotherapy in Gastrointestinal Cancer Patients in China

Abstract 1423: Harnessing the gut microbiome to modulate immune checkpoint blockade response in triple-negative breast cancer

The Gut Microbiome is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer

Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy

IDDF2024-ABS-0113 the Mechanism of the Efficacy of Pasteurized Bacteroides Thetaiotaomicron Sensitizing PD-1 Inhibitor by Remodeling MSI-L Colorectal Cancer Immune Micro-Environment

The gut microbiota modulates responses to anti-PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors

The biotherapeutic Clostridium butyricum MIYAIRI 588 strain potentiates enterotropism of Rorγt+Treg and PD-1 blockade efficacy

Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Abstract 1422: A novel gut microbiota therapeutic approach for enhancing immune checkpoint inhibitor therapy

Abstract B39: Modulation of cancer immunotherapy by the microbiome: Insights from computational analyses of preclinical studies

Abstract 1825: A bacterial consortium engineered from feces of patients responding to anti-PD1 treatment mediates tumor response through IFNγ in non-small cell lung cancer

Abstract 3733: Gut microbiota-dependent bile acidtaurodeoxycholic acid, TDCAfacilitates anti-tumor immune responses by modulating cytotoxic CD8 T cell immunity

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers

Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy

Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors

Gut microbiome affects the response to immunotherapy in non-small cell lung cancer

Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor

Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome

Abstract 719: A tumor-activated PD1/IL2 bispecific molecule, designed to overcome IL-2 receptor-mediated clearance, improve tolerability and stimulate antigen-experienced CD8+ T cells in the tumor microenvironment of murine models